AGIOS PHARMACEUTICALS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0.1 | $<0.1 | $<0.1 | $<0.1 | $0.0 |
| Operating income | -$0.5 | -$0.4 | -$0.4 | -$0.4 | -$0.4 |
| Net income | -$0.4 | $0.7 | -$0.4 | -$0.2 | $1.6 |
| Cash Flow Statement | |||||
| Free cash flow | -$0.4 | -$0.4 | -$0.3 | -$0.3 | -$0.4 |
| Share repurchases | — | — | $0.0 | $0.0 | $0.8 |
Shares outstanding 59.7M · Free float 87.5%
Annual filing data through FY ended December 31, 2025; float as of September 29, 2026.